Amicus Therapeutics, Inc. (FOLD) Earnings History
Net Loss21 years of earnings data (2005–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Amicus Therapeutics, Inc. (FOLD) Earnings Overview
As of June 23, 2026, Amicus Therapeutics, Inc. (FOLD) reported trailing twelve-month net income of -$27M, reflecting +51.2% year-over-year growth. The company earned $-0.09 per diluted share over the past four quarters, with a net profit margin of -4.3%.
Looking at the long-term picture, FOLD's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2009.
Amicus Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), SRPT ($65M net income, -32.5% margin), BMRN ($269M net income, 10.8% margin), FOLD has outperformed on profitability metrics. Compare FOLD vs RARE →
FOLD Earnings vs Peers
Earnings metrics vs comparable public companies
FOLD Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$27M | +51.7% | $34M | $-0.09 | -4.3% | 5.4% |
| 2024 | -$56M | +63.0% | $25M | $-0.18 | -10.6% | 4.7% |
| 2023 | -$152M | +35.9% | -$77M | $-0.51 | -38.0% | -19.3% |
| 2022 | -$237M | +5.5% | -$212M | $-0.82 | -71.9% | -64.4% |
| 2021 | -$250M | +9.5% | -$206M | $-0.92 | -82.0% | -67.6% |
| 2020 | -$277M | +22.3% | -$247M | $-1.07 | -106.1% | -94.7% |
| 2019 | -$356M | -2.1% | -$304M | $-1.48 | -195.6% | -166.8% |
| 2018 | -$349M | -22.9% | -$329M | $-1.88 | -382.5% | -360.3% |
| 2017 | -$284M | -42.0% | -$442M | $-1.85 | -769.0% | -1196.8% |
| 2016 | -$200M | -51.4% | -$182M | $-1.49 | -4034.7% | -3668.6% |
| 2015 | -$132M | -91.7% | -$130M | $-1.20 | - | - |
| 2014 | -$69M | -15.6% | -$69M | $-0.93 | -5631.2% | -5612.8% |
| 2013 | -$60M | -22.2% | -$64M | $-1.16 | -16427.8% | -17680.7% |
| 2012 | -$49M | -9.8% | -$53M | $-1.07 | -265.0% | -287.5% |
| 2011 | -$44M | +19.2% | -$51M | $-1.28 | -207.2% | -237.4% |
| 2010 | -$55M | -736.5% | -$56M | $-1.98 | -5958.4% | -6056.2% |
| 2009 | -$7M | +83.3% | -$7M | $-0.29 | -10.2% | -11.4% |
| 2008 | -$39M | +4.4% | -$44M | $-1.75 | -262.9% | -293.7% |
| 2007 | -$41M | +11.2% | -$46M | $-3.11 | -2307.6% | -2567.5% |
| 2006 | -$46M | -132.0% | -$47M | $-62.97 | - | - |
| 2005 | -$20M | - | -$21M | $-48.69 | - | - |
Download Data
Export FOLD earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
21+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
FOLD — Frequently Asked Questions
Quick answers to the most common questions about buying FOLD stock.
What is FOLD earnings per share (EPS)?
FOLD trailing twelve-month (TTM) diluted EPS is $-0.09, reflecting +51.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2005 to 2025 is available in the table on this page.
What is Amicus Therapeutics, Inc.'s net income?
Amicus Therapeutics, Inc. (FOLD) trailing twelve-month net income is $-27M as of 2025. Earnings grew +51.2% year-over-year.
Is FOLD profitable?
FOLD is not currently profitable on a TTM basis, reporting a net loss of $-27M. Net margin is -4.3%. Investors should monitor for a return to profitability.
What is FOLD's earnings growth rate?
FOLD compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2005 to 2025.
What are FOLD's profit margins?
Amicus Therapeutics, Inc. net profit margin is -4.3%, operating margin is +5.4%, and gross margin is +87.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -11.6%.
Is FOLD growing earnings?
Yes, FOLD earnings are accelerating — EPS growth of +51.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-27M. Earnings momentum is strengthening.
What was FOLD's best earnings year?
Amicus Therapeutics, Inc.'s highest annual net income on record is $-7M, achieved in fiscal year 2009. Earnings history on this page spans 2005 to 2025 and includes all annual and quarterly figures.
What were FOLD's earnings last quarter?
FOLD's most recent reported quarter was Q4 2025. Net income was $2M with diluted EPS of $0.01. For a full breakdown of all quarters, see the quarterly earnings table on this page.